Kymera Therapeutics (KYMR) Advances KT 579 And KT 621, Is It Still 6% Undervalued?

Simply Wall St.11-07

Kymera Therapeutics (KYMR) is back in focus after reporting a third quarter net loss of US$132 million and a nine month net loss of US$262.44 million, even as interest around KT-579 and KT-621 remains...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681111811?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-07 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681111811","market":"sg","top_or_hot":-1,"title":"Kymera Therapeutics (KYMR) Advances KT 579 And KT 621, Is It Still 6% Undervalued?","media":"Simply Wall St.","content":"<div>\n<p>Kymera Therapeutics (KYMR) is back in focus after reporting a third quarter net loss of US$132 million and a nine month net loss of US$262.44 million, even as interest around KT-579 and KT-621 remains...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera Therapeutics (KYMR) Advances KT 579 And KT 621, Is It Still 6% Undervalued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera Therapeutics (KYMR) Advances KT 579 And KT 621, Is It Still 6% Undervalued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-07 15:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kymera Therapeutics (KYMR) is back in focus after reporting a third quarter net loss of US$132 million and a nine month net loss of US$262.44 million, even as interest around KT-579 and KT-621 remains...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st","article_id":"2681111811","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-advances-kt-579-and-kt-621-is-it-st","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681111811","pubTimestamp":1794036875,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KYMR":"Kymera Therapeutics, Inc."},"translate_title":"Kymera Therapeutics (KYMR) 推进 KT 579 和 KT 621，是否仍被低估 6%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1.5},"content_text":"Kymera Therapeutics (KYMR) is back in focus after reporting a third quarter net loss of US$132 million and a nine month net loss of US$262.44 million, even as interest around KT-579 and KT-621 remains strong. Kymera Therapeutics’ latest net loss figures land against a backdrop of strong price gains, with the share price at US$131.73 after a 30 day share price return of 21.58% and an 81.05% share price return year to date. The 1 year total shareholder return of 124.57% and very large 3 year total shareholder return above 7x suggest momentum has been building as investors weigh the KT-579 and KT-621 clinical updates against a valuation that already prices in a lot of future execution risk. Spot 19 high quality undiscovered gems that, like Kymera Therapeutics, pair early-stage clinical momentum with strong fundamentals and may still be flying under most investors’ radar.\nAfter a move like Kymera Therapeutics just posted, the dilemma is simple enough. Step in after a sharp run, or wait and risk watching the valuation run further without you as the numbers get picked apart next. AdvertisementMost Popular Narrative: 6% Undervalued Kymera Therapeutics last closed at $131.73, just under a narrative fair value estimate of $139.83 that assumes meaningful progress from KT-621 and KT-579 over the next few years.  The main requirement for this thesis is successful late-stage development and regulatory progression of KT-621 in atopic dermatitis and asthma, alongside KT-579 in lupus, while managing rising R&D and G&A spending within the current cash runway that is guided into 2029.  See why 6 investors see Kymera Therapeutics as 6% undervalued. Result: Fair Value of $139.83 (UNDERVALUED) Still, Kymera Therapeutics carries real execution risk if heavy quarterly R&D and G&A spending strains the cash runway, or if shareholder investigations dampen market confidence. Find out about the key risks to this Kymera Therapeutics narrative. Another View: What Kymera Therapeutics’ Valuation Ratio Says The fair value story for Kymera Therapeutics leans on analyst targets and long range earnings assumptions. A simple P/B check tells a very different story. The stock trades around 7x book value, compared with about 1.7x for the US Biotechs industry and roughly 5.7x for peers, which points to a rich premium rather than a cheap entry point. If that gap closed, how much of the current narrative would still hold up for you as a shareholder? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:KYMR P/B Ratio as at Nov 2026Next Steps Plenty in this Kymera Therapeutics story points in different directions, which is exactly why the next move should be yours and yours alone. Weigh both the concern around downside risk and the optimism around potential upside by reviewing the 1 key reward and 4 important warning signs. Looking for more investment ideas beyond Kymera Therapeutics? If Kymera Therapeutics has your attention, do not stop there. Broader opportunity often comes from scanning multiple angles before committing fresh capital.  Spot potential mispricings early by reviewing companies filtered as 39 high quality undervalued stocks that align with strong business quality and more reasonable expectations. Prioritise resilience by scanning a 29 resilient stocks with low risk scores that focuses on businesses with steadier profiles when market sentiment turns jumpy. Target stronger financial foundations by working through a list of solid balance sheet and fundamentals (24 results) that highlights firms with healthier debt levels and sturdier fundamentals.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Kymera Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681111811","isCrawlerRequest":true}